Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 1979 Jul 27;94(3):257-63.
doi: 10.1007/BF00419285.

Cyclophosphamide-resistant Yoshida ascites tumor cells and their cross resistance to some alkylating agents

Comparative Study

Cyclophosphamide-resistant Yoshida ascites tumor cells and their cross resistance to some alkylating agents

H H Gerhartz et al. J Cancer Res Clin Oncol. .

Abstract

A cyclophosphamide-resistant subline of a Yoshida ascites tumor was developed by giving increasing doses of the drug after transplantation. The effect of several alkylating agents on the cell proliferation of both the sensitive and resistance cell line was compared establishind dose response curves and D50 values. The developed subline revealed a 260 fold resistance to cyclophosphamide. It was completely cross-resistant to hydroperoxycyclophosphamide, whereas for triaziquone, N-oxide-mustard, and N-methyl-mustard only a partial cross resistance existed. These results give further evidence that cyclophosphamide and hydropeoxycyclophosphamide have the same mechanism of action. Regarding the other alkylating agents the results demonstrate differences concerning either the molecular mode of action or protecting effects. A decreased activation or uptake of substance is probably not the base for resistance.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Cancer Res. 1969 Jun;29(6):1184-94 - PubMed
    1. Cancer Treat Rep. 1976 Apr;60(4):355-9 - PubMed
    1. Cancer Res. 1969 Apr;29(4):873-9 - PubMed
    1. Cancer Res. 1965 Oct;25(9):1581-95 - PubMed
    1. Cancer Treat Rep. 1976 Apr;60(4):423-7 - PubMed

Publication types